About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Letter to the Editor
In a retrospective study to assess the use of antithrombin concentrates, the authors judged the plasma-derived product (Thrombate III) to be more cost-effective than the recombinant human form (ATryn) for patients with hereditary antithrombin deficiency.
Cristina M. Salas, PharmD; and Marta A. Miyares, PharmD, BCPS (AQ Cardiology)
Calculating the Dose of Subcutaneous Immunoglobulin for Primary Immunodeficiency Disease in Patients Switched From Intravenous to Subcutaneous Immunoglobulin Without the Use of a Dose-Adjustment Coefficient
Intravenous immunoglobulin (IVIG), a standard therapy for immune deficiency disorders, is not appropriate for all patients. As a result, a subcutaneous form (SCIG) has emerged as an alternative. The authors propose a tailored dosing approach for SCIG.
Michael Fadeyi, PharmD, MS; and Tin Tran, RPh
Rheumatology topics included therapies for rheumatoid arthritis, psoriatic arthritis, and Behçet’s syndrome. At the TCT meeting, researchers examined the effects of pharmacological strategies for myocardial infarction, along with platelet function testing
as a guide to antiplatelet therapy.
Experts Comment on Recent Developments
Part 1 covers promising biologics that aim to promote safety and efficacy in treating psoriatic lesions. Part 2 addresses the problem of nonadherence to treatment.
Peter Sonnenreich, MA
Facilities Able to Scan Unique Device Identifiers Will Benefit
New FDA rules on medical devices shouldn’t be a burden for hospitals that can scan unique device identifiers.
Avoiding Pitfalls in Conducting a Root Cause Analysis
Matthew Grissinger, RPh, FASCP
Glucarpidase (Voraxaze) for methotrexate toxicity
Mohammad A. Rattu, PharmD; Neal Shah, PharmD; Jessica M. Lee, PharmD; Antony Q. Pham, PharmD, BCPS; and Nino Marzella, BS, MS, PharmD
Duavee, an oral contraceptive; riociguat (Adempas) for two types of pulmonary hypertension; and macitentan (Opsumit) for pulmonary arterial hypertension
Marvin M. Goldenberg, PhD, RPh, MS
FDA approvals, drug indications, and updates